Takeda Inks Deal To Develop Anti-Obesity Drugs With LG Life Sciences
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement is one of three announced by Takeda March 30, including a deal to develop cancer compounds with CanBas.
You may also be interested in...
Takeda To Help Develop Lundbeck's First-In-Class Mood Disorder Candidates In Japan, U.S.
Takeda Pharmaceutical has taken a step to round out its pipeline by adding mood and anxiety disorder candidates under an agreement with Danish pharma H. Lundbeck
Takeda To Help Develop Lundbeck’s First-In-Class Mood Disorder Candidates In Japan, U.S.
Deal includes $40 million upfront payment and potential $345 million in milestones for Lundbeck.
Takeda To Help Develop Lundbeck’s First-In-Class Mood Disorder Candidates In Japan, U.S.
Deal includes $40 million upfront payment and potential $345 million in milestones for Lundbeck.